Alzheimer’s drug slows mental, functional decline in Eli Lilly trial
By
Alicia Lasek
Jan 12, 2021
Participants who took donanemab for 76 weeks showed 32% slower decline in thinking and daily function compared with those in a placebo group.
Drug that targets Alzheimer’s inflammation approved for trial by FDA
By
Alicia Lasek
Feb 09, 2021
An experimental drug meant to treat the “type 3 diabetes” that some scientists believe triggers Alzheimer’s has been approved for a late-stage clinical trial.
LTC research hub to bring clinical trials to rural residents
By
Alicia Lasek
Sep 16, 2022
Nursing home operator Principle LTC and Care Access, a research organization, have launched a new research hub in Raleigh, NC, to provide rural residents access to clinical trials.